SCHEMBL19464801

SCHEMBL19464801

CC(C)(C)N1CCN(C(=O)CCCCCN)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GNAI3 P08754 6/20 0.49
▸ GNAI1 P63096 6/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ GNAO1 P09471 5/20 0.43
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ PAOX Q6QHF9 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ ITGB3 P05106 2/20 0.39
▸ ITGA2B P08514 2/20 0.39
▸ LMNA P02545 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ PLG P00747 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ SLC6A2 P23975 1/20 0.38
▸ RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16133079 0.86 SIGMAR1 (0.42) GNAI3GNAI1L3MBTL1MEN1KMT2A
SCHEMBL20466516 0.86 HRH3 (0.49) GNAI3GNAI1L3MBTL1GNAO1MEN1
SCHEMBL16219522 0.85 GNAI3 (0.63) GNAI3GNAI1L3MBTL1GNAO1MEN1
Ammonia Solution, Strong SCHEMBL3990591 0.84 GNAI3 (0.55) GNAI3GNAI1L3MBTL1GNAO1MEN1
SCHEMBL21664654 0.83 L3MBTL1 (0.65) GNAI3GNAI1L3MBTL1GNAO1MEN1
SCHEMBL18591779 0.81 L3MBTL1 (0.44) GNAI3GNAI1L3MBTL1GNAO1MEN1
SCHEMBL12139779 0.81 L3MBTL1 (0.56) GNAI3GNAI1L3MBTL1GNAO1MEN1
SCHEMBL16221897 0.81 GNAI3 (0.53) GNAI3GNAI1L3MBTL1GNAO1MEN1
SCHEMBL5243155 0.81 GNAI3 (0.72) GNAI3GNAI1L3MBTL1GNAO1MEN1
SCHEMBL5244391 0.81 GNAI3 (0.62) GNAI3GNAI1L3MBTL1GNAO1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220127613-A1 Functionally-Modified Oligonucleotides And Subunits Thereof SAREPTA THERAPEUTICS INC (US) 2022-04-28 — — US disclosed
US-11208655-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2021-12-28 — — US disclosed
US-20200115709-A1 Functionally-Modified Oligonucleotides And Subunits Thereof JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2020-04-16 — — US disclosed
US-10344281-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2019-07-09 — — US disclosed
US-20180223278-A1 Functionally-Modified Oligonucleotides And Subunits Thereof JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2018-08-09 — — US disclosed
US-9790499-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2017-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180223278-A1 Functionally-Modified Oligonucleotides And Subunits Thereof RTCB, NSUN3, NSUN2 GNAI3 1942/4885GNAI1 2223/4885L3MBTL1 28/4885
US-11208655-B2 Functionally-modified oligonucleotides and subunits thereof RTCB, NSUN3, NSUN2 GNAI3 1942/4885GNAI1 2223/4885L3MBTL1 28/4885
US-20200115709-A1 Functionally-Modified Oligonucleotides And Subunits Thereof RTCB, NSUN3, NSUN2 GNAI3 1942/4885GNAI1 2223/4885L3MBTL1 28/4885
US-10344281-B2 Functionally-modified oligonucleotides and subunits thereof RTCB, NSUN3, NSUN2 GNAI3 1942/4885GNAI1 2223/4885L3MBTL1 28/4885
US-20220127613-A1 Functionally-Modified Oligonucleotides And Subunits Thereof RTCB, NSUN3, NSUN2 GNAI3 1942/4885GNAI1 2223/4885L3MBTL1 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback